Dihexa
Also known as PNB-0408 · angiotensin IV analog
Potent procognitive angiotensin IV–related compound; extremely experimental with safety unknowns.
How to picture it
Dihexa is a potent neurotrophic research molecule associated with HGF/c-Met signaling and synaptogenesis — framed as accelerating the brain's ability to build and reinforce connections. Picture structural plasticity work: not a caffeine-style jolt, but growth-factor pathway engagement for memory and cognitive architecture research. The educational frame is "build more wiring," not "speed up the clock."
Research focus & benefits
- Synaptogenesis and HGF/c-Met pathway research
- Memory and cognitive architecture studies
- Neurotrophic potency interest in preclinical work
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Dihexa is a blood-brain-barrier-penetrant small peptide-like compound derived from angiotensin IV research, reported to have very strong procognitive effects in animal models via HGF/c-Met signaling. Human safety data are sparse. It is high-risk experimental territory, not a casual nootropic.
Mechanism
Enhances hepatocyte growth factor (HGF)/c-Met signaling implicated in synaptogenesis.
Research uses
- Alzheimer and cognitive deficit animal models
- Synaptogenesis research
Research dosing notes
No established human therapeutic dose. Extreme caution — oncology signaling concerns are theoretical flags.
Half-life / kinetics
Longer than many peptides; oral discussion exists in research contexts
Common research routes
Reported considerations
- Unknown human profile
- Theoretical cancer-pathway concerns via c-Met
- Headache/irritability anecdotal
Contraindications / cautions
- History of cancer
- Pregnancy
- Anyone seeking proven clinical nootropics
Common research stacks
- Not recommended for casual stacking
Legal / access note
Unapproved experimental compound. Not a consumer cognitive enhancer.